Merged brand Kapadi, the unified brand from the OncoBay Clinical merger with Clinscience and Exom Group, presents a broader global oncology CRO offering. This signals an expanded service footprint and credibility when engaging large pharma and biotech firms seeking integrated technology- and data-driven trial solutions.

Immuno-oncology focus Specialization in immuno-oncology and cell therapy positions Kapadi to pursue opportunities with sponsors developing IO products and cell-based therapies, where end-to-end control, integrated manufacturing, and specialized site networks are differentiators.

End-to-end capabilities Kapadi’s emphasis on end-to-end control—from scientific expertise to integrated cell manufacturing and streamlined technology frameworks—offers a compelling value proposition for sponsors seeking simplified, risk-managed, full-service CRO partnerships for complex oncology programs.

Strategic partnerships Historically active collaborations with Leukemia & Lymphoma Society, Hillstream BioPharma, Chimeric Therapeutics, Protocol First, and others illustrate a track record of alliance-driven growth. This can be leveraged to approach sponsors with collaboration-ready case studies and joint development opportunities.

Growth and funding signals With revenue in the lower end of the mid market and a lean employee base, Kapadi appears poised for targeted expansion into mid- to large-scale oncology trials. This suggests sales opportunities in mid-size biotechs and specialty pharma looking to scale IO programs without the overhead of larger CROs.